Compare HMR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMR | MAIA |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 79.0M |
| IPO Year | 2024 | 2022 |
| Metric | HMR | MAIA |
|---|---|---|
| Price | $1.39 | $1.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 50.8K | ★ 328.5K |
| Earning Date | 06-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $64.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.87 |
| 52 Week High | $1.71 | $3.19 |
| Indicator | HMR | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 48.28 |
| Support Level | $1.03 | $1.23 |
| Resistance Level | $1.71 | $1.46 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 58.82 | 20.69 |
Heidmar Maritime Holdings Corp is a commercial and technical management company that operates tanker and dry-bulk vessel pools. The group, along with its subsidiaries, operates as a growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. Its lines of business currently include asset management, tanker pooling, commercial and time charters, assisting clients with the buying and selling of ships, and technical management services for individual vessels, which include assistance in technical operations and crewing of the vessel. Its geographic areas are Singapore, the USA, the Marshall Islands, the United Arab Emirates, Germany, Switzerland, and Other.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.